The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence

Annals of the New York Academy of Sciences

Volumn 1025, Issue , 2004, Pages 296-306

  Yui, Kunio ^a   Goto, Kimihiko ^b   Ikemoto, Shigenori ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Dopamine; Flashbacks; Hyperactivity; Methamphetamine (MAP); Plasma norepinephrine; Psychosis; Psychosocial stressors

Indexed keywords

3 O METHYLDOPAMINE; METHAMPHETAMINE; MONOAMINE; NORADRENALIN;

AUDITORY HALLUCINATION; BLOOD LEVEL; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; PSYCHOSIS; RECURRENT DISEASE; SOCIAL PSYCHOLOGY; STRESS; VISUAL HALLUCINATION;

EID: 10444248145     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1316.037     Document Type: Conference Paper

References (34)

1. YUI, K., K. GOTO, S. IKEMOTO & T. ISHIGURO. 1997. Methamphetamirie psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. J. Clin. Psychopharmacol. 17: 34-43.
2. YUI, K., K. GOTO, S. IKEMOTO, et al. 1999. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol. Psychiatry 4: 512-523.
3. YUI, K., K. GOIO, S. IKEMOTO & T. ISHIGURO. 2000. Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity. J. Clin. Psychopharmacol. 20: 165-174.
4. ELLICOTI, A., C. HAMMEN, M. GITLIN, et al. 1990. Life events and the course of bipolar disorder. Am. J. Psychiatry 147: 1194-1198.
5. POST, R.M. 1992. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 149: 999-1010.
6. HALL, K.S., D.L. DUNNER, G. ZELLER & R.R. FIEVE. 1997. Bipolar illness: a prospective study of life events. Compr. Psychiatry 18: 497-502.
7. SPIELBERGER, C.D. 1983. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press. Palo Alto, CA.
8. MATHEW, R.J., B.T. Ho, P. KRALIK, et al. 1981. Catecholamines and monoamine oxidase activity in anxiety. Acta Psychiatr. Scand. 63: 245-252.
9. MILLNS, H., M. WOODWARD & C. BOLTON-SMITH. 1995. Is it necessary to transform nutrient variables prior to statistical analyses? Am. J. Epidemiol. 141: 251-262.
10. HAVILCEK, L.L. & R.D. CRAIN. 1988. Practical Statistics for Physical Sciences. American Chemical Society. Washington, DC.
11. ANISMAN, H. & R.M. ZACHARKO. 1995. Behavioral and neurochemical consequences associated with stressors. Ann. N.Y. Acad. Sci. 771: 205-225.
12. IRWIN, J., P. AHILUWALIA & H. ANISMAN. 1986. Sensitization of norepinephrine activity following acute and chronic footshock. Brain Res. 379: 98-103.
13. ADDIGTON, J. & D. ADDFIGTON. 1998. Effect of substance misuse in early psychosis. Br. J. Psychiatry 172: 134-136.
14. ROBINSON, T.E., J.B. BECKER, E.A. YOUNG, et al. 1987. The effects of footshock stress on regional brain dopamine metabolism and pituitary β-endorphin release in rats previously sensitized to amphetamine. Neuropharmacology 26: 679-691.
15. WOOD, P.L & C.A. ALTAR. 1988. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40: 163-187.
16. HEAL, D.J., A.T.J. FRANKLAND & W.R. BUCKETT. 1990. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detention studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 29: 1141-1150.
17. KENT, A.P., G.M. STERN & R.A. WEBSTER. 1990. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat. Br. J. Pharmacol. 100: 743-748.
18. DALMAZ, Y. & L. PEYRIN. 1978. Relations entre Ia 3- méthoxytyramine urinaire et le metabolisme péripherioque de Ia dopamine chez l'homme et chez l'enfant. Arch. Int. Physiol Biochem. 86: 257-270.
19. CHARPUSTA, S.J., R.J. WYATT & J.M. MASSERANO. 1997. Effects of single and repeated footshock on dopamine release and metabolism in the brains of fisher rats. J. Neurochem. 68:2024-2031.
20. BREMNER, J.D., J.H. KRYSTAL, S.M. SOUTHWICK & D.S. CHARNEY. 1995. Functional neuroanatomical correlates of the effects of stress on memory. J. Traumatic Stress 8: 527-553.
21. SOUTHWICK, S.M., J.H. KRYSTAL, A. MPRGAM, et al. 1993. Abnormal noradrenergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 50: 266-274.
22. ROY, A., D. PICKAR, J. D. JONG, et al. 1988. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Arch. Gen. Psychiatry 45: 849-857.
23. KENT, A.P., G.M. STERN & R.A. WEBSTER. 1990. The effect of benserazide on the peripheral and central distribution and metabolism of lovodopa after acute and chronic administration in the rat. Br. J. Pharmacol. 100: 743-748.
24. PÉRONNET, F., P. BLIER, G. BRISSON, et al. 1986. Plasma catecholamines at rest and exercise in subjects with high- and low-trait anxiety. Psychosom. Med. 48: 52-58.
25. DIMSDALE, J.E. & J. MOSS. 1980. Plasma catecholamines in stress and exercise. JAMA 243: 340-342.
26. GREEN, A.I., M.Y. ALAM, R.A. BASHES, et al. 1993. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res. 10: 33-37.
27. RISBO, A., K. JESSEN & J.O. HAGELSTEN. 1983. Catecholamine response to the clinical use of alpha adrenergic receptor blocking agents. Acta Anaesthesiol. Scand. 27: 72-74.
28. BREIER, A., R.W. BUCHANAN, R.W. WALTRIP II, et al. 1994. The effect of clozapine on plasma norepinephrine: relationship to Clinical efficacy. Neuropsychopharmacology 10: 1-7.
29. TUCK, J.R. 1973. Effects of chlorpromazine, thioridazine and haloperidol on adrenergic transmitter mechanisms in man. Eur. J. Clin. Pharmacol. 6: 81-87.
30. NAGAOKA, S., N. IWAMOTO & H. ARAI. 1997. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to haloperidol treatment. Biol. Psychiatry 41: 857-864.
31. BROWN, A.S., G. GEWIRTZ, J. HARKAVY-FRIEDMAN, et al. 1987. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 17: 317-325.
32. CASTELLANI, S., M.G. ZIEGLER, O.P. VAN KAMMEN, et al. 1982. Plasma norepinephrine and dopamine-13-hydroxylaseactivity in schizophrenia. Arch. Gen. Psychiatry 9: 1145-1149.
33. WESTERINK, B.H.C. & S.J. SPAAN. 1982. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J. Neurochem. 38: 680-686.
34. VON VOIGTLANDER, P.F., M.A. BURIAN, T.S. ALTHAUS & L.R. WILLIAMS. 1990. Effects of chronic haloperidol on vitamin E levels and monoamine metabolism in rats fed normal and vitamin E deficient diets. Res. Commun. Chem. Pathol. Pharmacol. 68: 343-352.